Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

placebo and active controlled trial with four treatment arms; elagolix 150 mg, elagolix 250 mg, leuprolide depot, and placebo. We expect top-line data based on the first three months of placebo and active controlled treatment to be available later in the fourth quarter.

An abstract providing Petal Study (0603) clinical efficacy and safety data was presented at the American Society for Reproductive Medicine in Atlanta, on October 21, 2009.

Urocortin 2 Update

The Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with Neurocrine, has obtained regulatory approval to begin a pilot study in patients with Acute Decompensated Heart Failure. These patients are the target population for the Urocortin 2 mechanism of action and the investigational intervention will be compared to standard-of-care treatment; enrollment of 50 subjects is underway.

VMAT2 Update

The highly selective blockade of the Vesicular Monoamine Transporter 2 (VMAT2) with NBI-98854 should be of clinical benefit in patients with a variety of CNS diseases, especially those with involuntary hyperkinetic movement disorders such as Tardive Dyskinesia. During August 2009, we initiated a single ascending dose Phase 1 study in Canada. Pending successful completion and evaluation of this initial Phase I study, we expect to launch a second Phase I study assessing multiple repeated doses of NBI-98854 in early 2010.

Conference Call and Webcast Thursday, October 29, 2009 at 8:30a.m. EDT

Neurocrine will hold a live conference call and webcast tomorrow morning, Thursday, October 29, 2009 at 8:30 a.m. Eastern Daylight Time (5:30 a.m. Pacific Daylight Time). Participants can access the live conference call by dialing 1-800-894-5910 (US) or 785-424-1052 (International) using the conference passcode 7NEURO. The call can also be ac
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors ... be able to protect their most important ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... Medical Device Industry, it steadfastly remains one ... cases involving IP infringement. This litigious nature ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 /PRNewswire-USNewswire/ ... been certified as a Medical Fitness Center by ... medically integrated health and fitness centers to achieve ... Center is the only certified fitness center in ... area. "The certification means the Cadence ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ... aspects in today,s growth in the pharmaceutical ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
(Date:4/14/2014)... by HIV/AIDS in South Africa may provide insight on ... issues in other areas of the world, which may ... could lead to successful interventions. , A report ... Nations mentions that due to the HIV/AIDS pandemic, which ... children are at an increased risk for mental health ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have ... Their Dental, Oral, and Craniofacial Manifestations." The complete ... Burke, Alison M. Boyce, Michael Collins, Brian L. ... Scott Ramnitz, Martha J. Somerman and J. Timothy ... the IADR/AADR Journal of Dental Research ...
(Date:4/14/2014)... IL A new study shows that moderate to ... increased risk of stroke, cancer and death. , Results ... moderate to severe obstructive sleep apnea were four times ... four times more likely to have a stroke (HR ... cancer (HR = 3.4), and 2.5 times more likely ...
(Date:4/14/2014)... 10, 2014. John DeLuca, PhD, and Yael Goverover, PhD, ... study how persons with multiple sclerosis (MS) perform everyday ... Reality to Measure Everyday Life Functional Activity in Multiple ... DeLuca is senior VP of Research & Training at ... York University, is a visiting scientist at Kessler Foundation. ...
(Date:4/14/2014)... a UT Dallas study involving serious youth offenders, the answer ... the next seven years: "How long do you think you,ll ... future encourages offending over time., Author Dr. Alex Piquero said ... life ahead of them offend at very high rates and ... to die much later in life offend much less., "In ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2
... ... in Europe to Treat Neovascular AMD Patients with New Epimacular Brachytherapy System , ... Fremont, CA and Pisa, ... patients have been treated following the commercialization of the VIDON® ANV® Therapy System, the ...
... 12 Zimmer Holdings, Inc. (NYSE: ... the Securities and Exchange Commission an automatic shelf registration statement on ... of equity and debt securities and that it intends, subject to ... a benchmark size. , The Company intends to use the ...
... PARI Respiratory Equipment launched a newly ... Efficient Aerosol Delivery, rounding out their free learning ... case managers, and pharmacists. The updated class ... for caregivers to update their skills and receive ...
... 12 Bausch & Lomb, the global eye health company, ... Board of Directors. , Mr. Hassan was chairman and ... Merck & Co., Inc. on November 3. Before joining Schering-Plough, ... chairman and CEO (from 2001 to 2003) of Pharmacia Corporation ...
... cancer cells in lab study , THURSDAY, Nov. 12 (HealthDay ... leukemia holds promise as a possible treatment for ovarian cancer, ... used to treat chronic myeloid leukemia. Researchers at the University ... the growth and invasive powers of ovarian cancer cells. ...
... , ... Nikolai Tankovich, MD, Ph.D., President and Chief Medical Officer of Stemedica Cell Technologies, ... Science and Society at Trinity College, a constituent college of the University of ... for stem cells, was attended by more than 300 professors and staff representing ...
Cached Medicine News:Health News:NeoVista, Inc. Announces First Neovascular AMD Patient Treated with VIDION ANV Therapy System in Europe Following Commercialization 2Health News:NeoVista, Inc. Announces First Neovascular AMD Patient Treated with VIDION ANV Therapy System in Europe Following Commercialization 3Health News:Zimmer Holdings, Inc. Announces Offering of Senior Notes 2Health News:PARI Respiratory Equipment Offers New Respiratory Management Course 2Health News:Fred Hassan Joins Bausch & Lomb Board of Directors 2Health News:Leukemia Drug May Help Some Ovarian Cancer Patients 2Health News:Stemedica President Invited To Lecture At The University Of Oxford 2Health News:Stemedica President Invited To Lecture At The University Of Oxford 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: